by ER German 2024 Cited by 5coronavirus disease (covid-19), covid long haul syndrome, long-haul covid, acyclovir therapy, covid 19. Introduction. The COVID-19 outbreak
1 and Type 2 Diabetes, PDF. Infections Vaccines. COVID-19, PDF. COVID-19 Acyclovir (Zovirax)
The following case series supports the efficacy of acyclovir use in patients with unique long-haul COVID-19 symptoms. The purpose of this series is to demonstrate atypical presentations of COVID-19 and explore acyclovir as a treatment option in these patients.
The excretion of Acyclovir can be decreased when combined with Favipiravir. Coronavirus Disease 2024 (COVID‑19) / Moderate to Severe COVID-19
In December 2024, the patient discontinued the use of acyclovir and reported the resolution of all previously experienced COVID-19 symptoms or sequelae. In 2024, the patient had no active COVID-19 infection and was no longer taking acyclovir.
Acyclovir. Varicella-zoster virus. Acyclovir. Varicella-zoster The reproductive number of COVID-19 is higher compared to SARS coronavirus.
- Acyclovir, Adefovir dipivoxil, Afatinib, Allopurinol Coronavirus Diseases 19 (COVID-19) guidelines. March 2024, version
In December 2024, the patient discontinued the use of acyclovir and reported the resolution of all previously experienced COVID-19 symptoms or sequelae. In 2024, the patient had no active COVID-19 infection and was no longer taking acyclovir.
We suggest the use of the antiviral medication, acyclovir, as a treatment for patients with long-term symptoms and unusual presentations of the virus, such as encephalopathy or coagulopathy. Keywords: acyclovir therapy; coronavirus disease (covid-19); covid 19; covid long haul syndrome; covid-19 neurological outcomes; covid-19-related
Comments
5